Nyxoah SA (NASDAQ:NYXH) is one of the

7 Fastest Growing European Stocks to Invest In. On March 23, 2026, Baird analyst David Rescott lowered the price target on Nyxoah SA (NASDAQ:NYXH) to $4.62 from $5.87 and maintained a Neutral rating, citing model updates as the company’s U.S. rollout begins to gain traction but remains in its early stages.

On March 20, 2026, Stifel lowered its price target on Nyxoah SA (NASDAQ:NYXH) to $10 from $11 previously and maintained a Buy rating, noting model adjustments tied to several moving parts.

On March 19, 2026, Nyxoah SA (NASDAQ:NYXH) reported Q4 EPS of (EUR 0.59), compared to (EUR 0.46) a year ago, with revenue of EUR 5.64M versus EUR 1.26M last year. Chief Executive Officer Olivier Taelman said the quarter marked the company’s first full period of U.S. commercialization, with revenue exceeding expectations and positive feedback from surgeons and patients, alongside consistent reimbursement from major payors and Medicare.

Copyright: kadmy / 123RF Stock Photo

The company expects U.S. net revenue to grow approximately 25% sequentially in both Q1 and Q2 of 2026, while international revenue is expected to follow typical seasonal patterns.

Nyxoah SA (NASDAQ:NYXH) develops neurostimulation therapies to treat obstructive sleep apnea.

While we acknowledge the potential of NYXH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.